Overview
JBIO market data
Price History
JBIO price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for JBIO. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Jade Biosciences Enters Exclusive Worldwide License Agreement With Paragon Therapeutics; To Pay Up To $22M In Milestone Payments To Paragon; To Pay Paragon Low To Mid-Single-Digit Percentage Royalties On Net Sales Of Licensed Products; Paragon Barred From New Campaigns Targeting Licensed Target For At Least Five YearsBenzinga · Jul 1, 2026, 9:25 PM
8-K filing — Jade Biosciences, Inc. (JBIO)SEC EDGAR · Jul 1, 2026, 8:41 PM
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsGlobenewswire Inc · Jun 26, 2026, 11:15 AM
UBS Initiates Coverage On Jade Biosciences with Buy Rating, Announces Price Target of $45Benzinga · Jun 15, 2026, 1:00 PM
Stock Market Today: S&P 500, Dow, Nasdaq Futures Fall As House Challenges Trump's Military Authority— Broadcom, CrowdStrike In Focus (UPDATED)Benzinga · Jun 4, 2026, 1:15 PM
Jade Biosciences Reveals Proposed Underwritten Public Offering; No Size DisclosedBenzinga · Jun 3, 2026, 8:10 PM
Wedbush Maintains Outperform on Jade Biosciences, Raises Price Target to $45Benzinga · Jun 2, 2026, 1:13 PM
Why Is Jade Biosciences Stock Trading Lower On Monday?Benzinga · Jun 1, 2026, 5:59 PM
BTIG Maintains Buy on Jade Biosciences, Raises Price Target to $74Benzinga · Jun 1, 2026, 4:44 PM
Jade Biosciences shares are trading lower. The company announced interim results from its Phase 1 trial evaluating JADE101, investigational anti-A Proliferation-Inducing Ligand monoclonal antibody in development for the treatment of immunoglobulin A nephropathy.Benzinga · Jun 1, 2026, 3:08 PM